Lumicitabine

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 18, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Health, Clinical medicine, Pneumoviridae, Healthcare-associated infections, Infectious causes of cancer, Human metapneumovirus, Hepatitis C, Hepatitis, Virus, Metapneumovirus, Lumicitabine

Replays of each event will be archived for at least 30 days.

Key Points: 
  • Replays of each event will be archived for at least 30 days.
  • Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases.
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection

Retrieved on: 
Tuesday, August 4, 2020
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Antivirals, Infectious diseases, Human orthopneumovirus, Paramyxoviridae, Antiviral drug, RSV, Drugs, Fast track, Lumicitabine, Respiratory syncytial virus vaccine

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.

Key Points: 
  • ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.
  • We are very pleased that sisunatovir has received Fast Track designation for the treatment of serious RSV, a significant global health concern, said Alex Sapir, CEO, ReViral.
  • A drug candidate with Fast Track designation is eligible for greater access to the FDA for the purpose of expediting the drug product candidate's development, review, and potential approval.
  • ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV).